OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
JOCI55

Jocil Ltd

Commodity ChemicalsVerified

Jocil Ltd maintains a strong liquidity position, with a current ratio of 3.48, indicating the company can easily cover its short-term liabilities with its short-term assets. The company's liquidity is further supported by INR 252.1 million in cash and equivalents, which provides a buffer against near-term operational needs. The debt-to-equity ratio of 0.03 suggests a conservative capital structure, with minimal reliance on long-term debt, which is consistent with the low liquidity risk assessment. In terms of profitability, Jocil Ltd's return on equity (ROE) of 0.8% and return on assets (ROA) of 0.61% are below the typical thresholds for the Commodity Chemicals industry, which often sees ROE and ROA in the 5-10% range. This suggests the company is underperforming relative to industry norms in terms of capital efficiency and asset utilization. The company's revenue is concentrated in a single business segment, as disclosed in its financials, with no geographic diversification provided in the available data. This lack of segment or geographic diversification increases the company's exposure to sector-specific risks, such as commodity price volatility and regulatory changes in the chemical industry. Looking ahead, Jocil Ltd's revenue is projected to remain relatively flat, with no significant growth expected in the current or next fiscal year based on the available outlook data. The company's capital expenditure of INR 34.5 million in the latest period suggests a modest investment in infrastructure, which may not be sufficient to drive meaningful revenue growth in a capital-intensive industry like chemicals. The risk assessment indicates a low probability of dilution in the near term, with no immediate filing-based flags for equity issuance or share buybacks. However, the company's low ROE and ROA suggest potential pressure to raise capital through equity or debt if profitability does not improve, which could lead to dilution in the future. Recent filings and transcripts do not highlight any major strategic shifts or operational disruptions. The company's financials remain stable, with no significant changes in operating cash flow or net income in the latest period. However, the absence of recent strategic announcements may indicate a lack of innovation or expansion plans, which could limit long-term growth potential.

30-day price · JOCI+34.32 (+34.1%)
Low$93.30High$149.70Close$135.11As of17 May, 00:00 UTC
Profile
CompanyJocil Ltd
TickerJOCI.NS
SectorBasic Materials
BusinessChemicals
Industry groupChemicals
IndustryCommodity Chemicals
AI analysis

Business. Jocil Ltd is a chemical manufacturing company that produces and sells commodity chemicals, primarily serving industrial and consumer markets.

Classification. Jocil Ltd is classified under the Basic Materials economic sector, Chemicals business sector, and Commodity Chemicals industry, with a confidence level of 0.92 based on verified market data.

Jocil Ltd maintains a strong liquidity position, with a current ratio of 3.48, indicating the company can easily cover its short-term liabilities with its short-term assets. The company's liquidity is further supported by INR 252.1 million in cash and equivalents, which provides a buffer against near-term operational needs. The debt-to-equity ratio of 0.03 suggests a conservative capital structure, with minimal reliance on long-term debt, which is consistent with the low liquidity risk assessment. In terms of profitability, Jocil Ltd's return on equity (ROE) of 0.8% and return on assets (ROA) of 0.61% are below the typical thresholds for the Commodity Chemicals industry, which often sees ROE and ROA in the 5-10% range. This suggests the company is underperforming relative to industry norms in terms of capital efficiency and asset utilization. The company's revenue is concentrated in a single business segment, as disclosed in its financials, with no geographic diversification provided in the available data. This lack of segment or geographic diversification increases the company's exposure to sector-specific risks, such as commodity price volatility and regulatory changes in the chemical industry. Looking ahead, Jocil Ltd's revenue is projected to remain relatively flat, with no significant growth expected in the current or next fiscal year based on the available outlook data. The company's capital expenditure of INR 34.5 million in the latest period suggests a modest investment in infrastructure, which may not be sufficient to drive meaningful revenue growth in a capital-intensive industry like chemicals. The risk assessment indicates a low probability of dilution in the near term, with no immediate filing-based flags for equity issuance or share buybacks. However, the company's low ROE and ROA suggest potential pressure to raise capital through equity or debt if profitability does not improve, which could lead to dilution in the future. Recent filings and transcripts do not highlight any major strategic shifts or operational disruptions. The company's financials remain stable, with no significant changes in operating cash flow or net income in the latest period. However, the absence of recent strategic announcements may indicate a lack of innovation or expansion plans, which could limit long-term growth potential.
Key takeaways
  • Jocil Ltd has a strong liquidity position with a current ratio of 3.48 and INR 252.1 million in cash and equivalents.
  • The company's ROE and ROA are below industry norms, indicating underperformance in capital efficiency and asset utilization.
  • Revenue is concentrated in a single business segment, increasing exposure to sector-specific risks.
  • No significant revenue growth is expected in the near term, with modest capital expenditure.
  • The risk of dilution is currently low, but weak profitability could lead to capital-raising pressures in the future.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyINR
Revenue$1.82B
Gross profit$393.4M
Operating income$15.5M
Net income$16.9M
R&D
SG&A
D&A
SBC
Operating cash flow$169.9M
CapEx-$34.5M
Free cash flow
Total assets$2.79B
Total liabilities$681.2M
Total equity$2.11B
Cash & equivalents$252.1M
Long-term debt$56.5M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$5.65B$150.1M$136.1M$89.9M
FY-3$7.54B$86.3M$71.3M$90.9M
FY-2$9.19B$115.0M$100.0M$134.9M
FY-1$7.53B-$9.8M$17.3M$21.6M
FY0$8.66B-$3.7M$10.2M-$34.2M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$2.52B$1.96B$83.5M
FY-3$2.57B$2.04B$21.5M
FY-2$2.54B$2.06B$2.7M
FY-1$2.79B$2.11B
FY0$2.88B$2.06B
PeriodOCFCapExFCFSBC
FY-4$141.5M-$75.7M$89.9M
FY-3-$169.9M-$21.9M$90.9M
FY-2$379.0M-$9.4M$134.9M
FY-1$169.9M-$34.5M$21.6M
FY0$104.2M-$87.8M-$34.2M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$1.82B$15.5M$16.9M
FQ-6$2.38B$19.7M$20.5M
FQ-5$2.30B$12.3M$11.5M
FQ-4$2.20B-$35.5M-$26.3M
FQ-3$1.78B-$299.0k$4.5M
FQ-2$2.70B$25.4M$22.2M
FQ-1$2.46B$23.9M$18.7M
FQ0$2.63B$20.2M$15.8M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$2.79B$2.11B$252.1M
FQ-6
FQ-5$3.27B$2.14B$162.7M
FQ-4
FQ-3$2.88B$2.06B$253.2M
FQ-2
FQ-1$2.90B$2.10B$44.2M
FQ0
PeriodOCFCapExFCFSBC
FQ-7$169.9M-$34.5M
FQ-6
FQ-5-$309.6M-$23.7M
FQ-4
FQ-3$104.2M-$87.8M
FQ-2
FQ-1-$419.2M-$13.3M
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$2.11B
Net cash$195.6M
Current ratio3.5
Debt/Equity0.0
ROA0.6%
ROE0.8%
Cash conversion10.0%
CapEx/Revenue-1.9%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Chemicals · cohort 1439 companies
MetricJOCIActivity
Op margin0.8%5.5% medp25 -0.0% · p75 10.8%below median
Net margin0.9%4.1% medp25 0.1% · p75 8.8%below median
Gross margin21.6%20.5% medp25 12.4% · p75 29.7%above median
R&D / revenue1.5% medp25 1.0% · p75 2.1%
CapEx / revenue-1.9%-6.2% medp25 -13.4% · p75 -2.6%top quartile
Debt / equity3.0%37.1% medp25 10.3% · p75 82.0%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-05 00:07 UTC#61825316
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 06:55 UTCJob: 790cfb14